Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | ADH1B | P00325 | 3/20 | 0.48 |
| ▸ | ADH1A | P07327 | 3/20 | 0.48 |
| ▸ | ADH7 | P40394 | 3/20 | 0.48 |
| ▸ | ADH1C | P00326 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | ADH4 | P08319 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6005313 | 0.96 | TSHR (0.58) | TSHRADH1BADH1AADH7ADH1C | |
| SCHEMBL7003589 | 0.94 | TSHR (0.56) | TSHRADH1BADH1AADH7ADH1C | |
| SCHEMBL222757 | 0.94 | TSHR (0.56) | TSHRADH1BADH1AADH7ADH1C | |
| SCHEMBL841504 | 0.86 | — | — | |
| SCHEMBL5651631 | 0.82 | CYP1A2 (0.52) | TSHRADH1BADH1AADH7ADH1C | |
| SCHEMBL14430277 | 0.81 | TSHR (0.70) | TSHRLMNAALDH1A1EPHX2CA12 | |
| SCHEMBL23876838 | 0.81 | DGKA (0.43) | TSHRADH1BADH1AADH7ADH1C | |
| SCHEMBL8176277 | 0.78 | CYP1A2 (0.52) | TSHRADH1BADH1AADH7ADH1C | |
| SCHEMBL39539 | 0.77 | — | — | |
| SCHEMBL2586098 | 0.77 | TSHR (0.64) | TSHRLMNAALDH1A1EPHX2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713806-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2013-05-08 | — | — | EP | claimed |
| WO-2021191035-A1 | DIOXAZOLINES AND THEIR USE AS HERBICIDES | BASF SE (DE) | 2021-09-30 | — | — | WO | disclosed |
| EP-2563847-B1 | MCR DENDRIMERS | LEIBNIZ INST FÜR PFLANZENBIOCHEMIE IPB (DE) | 2016-04-13 | — | — | EP | disclosed |
| US-8865863-B2 | MCR dendrimers | Leibniz-Institut fur Pflandzenbiochemie (DE) | 2014-10-21 | — | — | US | disclosed |
| US-8865863-B2 | MCR dendrimers | Leibniz-Institut fur Pflandzenbiochemie (DE) | 2014-10-21 | — | — | US | disclosed |
| US-20130203960-A1 | MCR DENDRIMERS | Leibniz-Institut fur Pflanzenbiochemie (DE) | 2013-08-08 | — | — | US | disclosed |
| US-20130203960-A1 | MCR DENDRIMERS | Leibniz-Institut fur Pflanzenbiochemie (DE) | 2013-08-08 | — | — | US | disclosed |
| WO-2011134607-A1 | MCR DENDRIMERS | LEIBNIZ-INSTITUT FÜR PFLANZENBIOCHEMIE (DE) | 2011-11-03 | — | — | WO | disclosed |
| WO-2007062314-A2 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070049620-A1 | Cyclic tertiary amine compound | SANKYO COMPANY, LIMITED (JP) | 2007-03-01 | — | — | US | disclosed |
| US-5155113-A | Administering 5-fluorouracil and derivatives with pyridine and pyridone derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| EP-0457195-A2 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-21 | — | — | EP | disclosed |
| US-5047521-A | Anticarcinogenic agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| EP-0436902-A1 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-17 | — | — | EP | disclosed |
| US-4983609-A | Anticancer agents | OTSUKA PHARMACEUTICAL (JP) | 1991-01-08 | — | — | US | disclosed |
| US-4864021-A | ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-09-05 | — | — | US | disclosed |
| EP-0323441-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-07-05 | — | — | EP | disclosed |
| EP-0247381-A2 | 5-flurorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-12-02 | — | — | EP | disclosed |
| EP-0180897-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049620-A1 | Cyclic tertiary amine compound | MYD88, IL5, BRD4 | TSHR 499/4885ADH1B 2746/4885ADH1A 2285/4885 |
| US-20130203960-A1 | MCR DENDRIMERS | MCRS1, APC, GRPR | TSHR 1634/4885ADH1B 3544/4885ADH1A 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.